Efficacy and safety comparison between pulsed dye laser and intense pulsed light configured with different wavelength bands in treating erythematotelangiectatic rosacea.

Previous clinical studies have shown that pulsed dye laser (PDL) and intense pulsed light (IPL) are effective for treating erythematotelangiectatic rosacea(ETR). This article aims to compare the efficacy and safety of PDL and IPL at three different wavelength bands (broad-band, single-narrow-band, and dual-narrow-band) in treating ETR. Sixty subjects with ETR were randomly categorized into four groups and received one of the following laser treatments: PDL (595 nm), IPL with Delicate Pulse Light (DPL, 500-600 nm), IPL with M22 590 (590-1200 nm), or IPL with M22 vascular filter (530-650 nm and 900-1200 nm). Four treatment sessions were administered at 4-week intervals, with one follow-up session 4 weeks after the final treatment. The efficacy of the four lasers was evaluated by comparing the clinical symptom score, total effective rate, VISIA red area absolute score, and RosaQoL score before and after treatment. The safety was evaluated by comparing adverse reactions such as pain, purpura, erythematous edema, and blister. All 60 subjects completed the study. Within-group effects showed that the clinical symptom score, VISIA red area absolute score, and RosaQoL score of all four groups were significantly reduced compared to before treatment (p < 0.001). Between-group effects showed no statistically significant difference among the four laser groups. Safety analysis showed that all four lasers were safe, but the incidence of blister was higher in the M22 vascular group. Nonpurpurogenic PDL, DPL, M22 590, and M22 vascular were equally effective in treating ETR and were well-tolerated. ClinicalTrial.gov Identifier: NCT05360251.

MiR-590-3p and its targets VEGF, PIGF, and MMP9 in early, middle, and late pregnancy: their longitudinal changes and correlations with risk of fetal growth restriction.

AIMS: The term "fetal growth restriction (FGR)" is commonly used to describe fetuses with an estimated fetal weight that is less than 10th percentile for gestational age. This study aimed to investigate the longitudinal change of microRNA-590-3p (miR-590-3p), vascular endothelial growth factor (VEGF), placental growth factor (PIGF), and matrix metalloproteinase (MMP)9 expressions in early, middle, and late pregnancy, and their correlations with the fetal growth restriction (FGR) risk. METHODS: Totally, 970 pregnant women in early pregnancy were enrolled, and their plasma samples were, respectively, acquired in early pregnancy (at 10th or 11th week of gestational age), middle pregnancy (at 20th or 21st week of gestational age), and late pregnancy (at 33th or 34th week of gestational age) for miR-590-3p, VEGF, PIGF, and MMP9 determinations. RESULTS: MiR-590-3p underwent a growing trend, but VEGF, PIGF, and MMP9 experienced declined trend along with pregnancy (all P < 0.001). Furthermore, the negative association of miR-590-3p with VEGF, PIGF, and MMP9 became stronger along with the pregnancy. Besides, miR-590-3p expression in middle and late pregnancy was higher, but VEGF, PIGF, and MMP9 expressions in middle and late pregnancy were lower in women affected by FGR compared to normal pregnant women (all P < 0.001). In addition, miR-590-3p, VEGF, PIGF, and MMP9 expression in middle and late pregnancy were of good value in predicting FGR risk. CONCLUSIONS: miR-590-3p exhibits a growing trend during pregnancy, and its expression in middle and late pregnancy is associated with increased FGR risk via interaction with VEGF, PIGF, and MMP9.